179 related articles for article (PubMed ID: 17220638)
41. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
[TBL] [Abstract][Full Text] [Related]
42. Salivary and lacrimal secretion is reduced in patients with ESRD.
Postorino M; Catalano C; Martorano C; Cutrupi S; Marino C; Cozzupoli P; Scudo P; Zoccali C
Am J Kidney Dis; 2003 Oct; 42(4):722-8. PubMed ID: 14520622
[TBL] [Abstract][Full Text] [Related]
43. Is there increasing evidence to change the management of renal bone disease?
Harum P
Nephrol News Issues; 1999 Apr; 13(4):55-6. PubMed ID: 10418451
[No Abstract] [Full Text] [Related]
44. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
Block GA; Klassen PS; Lazarus JM; Ofsthun N; Lowrie EG; Chertow GM
J Am Soc Nephrol; 2004 Aug; 15(8):2208-18. PubMed ID: 15284307
[TBL] [Abstract][Full Text] [Related]
45. Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders.
Chan WL; Rounsley K; Chapman E; Collings K; Dale C; De Waal S; Patel V; Tanner J; Turner E; Moore J; Borrows R
J Ren Nutr; 2010 Jul; 20(4):270-7. PubMed ID: 20362463
[TBL] [Abstract][Full Text] [Related]
46. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
[TBL] [Abstract][Full Text] [Related]
47. [Front line of management of hyperphosphatemia in hemodialysis patients].
Yumita S
Clin Calcium; 2004 May; 14(5):771-7. PubMed ID: 15577041
[TBL] [Abstract][Full Text] [Related]
48. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
Slatopolsky EA; Burke SK; Dillon MA
Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
[TBL] [Abstract][Full Text] [Related]
49. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
[TBL] [Abstract][Full Text] [Related]
50. Lanthanum carbonate--a first line phosphate binder?
de Freitas D; Donne RL; Hutchison AJ
Semin Dial; 2007; 20(4):325-8. PubMed ID: 17635822
[TBL] [Abstract][Full Text] [Related]
51. Factors for increased morbidity and mortality in uremia: hyperphosphatemia.
Levin NW; Gotch FA; Kuhlmann MK
Semin Nephrol; 2004 Sep; 24(5):396-400. PubMed ID: 15490397
[TBL] [Abstract][Full Text] [Related]
52. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle.
Al Aly Z; González EA; Martin KJ; Gellens ME
Am J Nephrol; 2004; 24(4):422-6. PubMed ID: 15308874
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.
Iwasaki Y; Takami H; Tani M; Yamaguchi Y; Goto H; Goto Y; Goto Y; Shigematsu T
Ther Apher Dial; 2005 Aug; 9(4):347-51. PubMed ID: 16076380
[TBL] [Abstract][Full Text] [Related]
54. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.
Liu YL; Lin HH; Yu CC; Kuo HL; Yang YF; Chou CY; Lin PW; Liu JH; Liao PY; Huang CC
Ren Fail; 2006; 28(8):701-7. PubMed ID: 17162430
[TBL] [Abstract][Full Text] [Related]
55. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
[TBL] [Abstract][Full Text] [Related]
56. Low prevalence of hyperphosphatemia independent of residual renal function in peritoneal dialysis patients.
Dong J; Wang H; Wang M
J Ren Nutr; 2007 Nov; 17(6):389-96. PubMed ID: 17971311
[TBL] [Abstract][Full Text] [Related]
57. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment.
Kestenbaum B
Semin Dial; 2007; 20(4):286-94. PubMed ID: 17635817
[TBL] [Abstract][Full Text] [Related]
58. Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
Shigematsu T; Ohya M; Negi S; Masumoto AR; Nakashima YM; Iwatani Y; Moribata MK; Yamanaka S; Tatsuta K; Mima T
Contrib Nephrol; 2015; 185():42-55. PubMed ID: 26023014
[TBL] [Abstract][Full Text] [Related]
59. [Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options].
Gallar P; Ortega O; Gutiérrez M; Muñoz M; Hilara L; Oliet A; Rodríguez I; Giménez E; Vigil A
Nefrologia; 2000; 20(4):355-61. PubMed ID: 11039261
[TBL] [Abstract][Full Text] [Related]
60. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.
Altmann P; Barnett ME; Finn WF;
Kidney Int; 2007 Feb; 71(3):252-9. PubMed ID: 17035945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
